AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist
Positive Clinical Update On Evusheld
Executive Summary
AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.
You may also be interested in...
AZ’s Evusheld Receives World-First Approval As COVID-19 Treatment, In Japan
Japan has approved Evusheld for both the prevention of infection in people who have not been exposed to the virus and, for the first time globally, as a treatment. The country's government will purchase 300,000 units from AZ amid global supplies that have been limited due to the surging need for the drug.
Coronavirus Update: Moderna’s Omicron Vaccine Study Successful, But Data Draw Skepticism
AstraZeneca also published efficacy data for Evusheld in patients with mild-to-moderate COVID-19, while Pfizer is investing $120m in expanding its Paxlovid manufacturing footprint in Michigan.
AstraZeneca’s Farxiga Flies Across $1bn Barrier
First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.